Douglass Winthrop Advisors LLC Sells 10,970 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Douglass Winthrop Advisors LLC has reduced its stake in IQVIA Holdings Inc. by 2.3%, selling 10,970 shares and owning 460,563 shares valued at approximately $81.2 million.
• Insider Keriann Cherofsky and Eric Sherbet sold a combined total of 6,349 shares, indicating a decrease in their positions by 15.87% and 17.59% respectively.
• Analysts have issued varied ratings on IQVIA, with a consensus rating of Moderate Buy and a price target averaging $228.62.

Douglass Winthrop Advisors LLC lessened its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 460,563 shares of the medical research company's stock after selling 10,970 shares during the quarter. Douglass Winthrop Advisors LLC owned about 0.27% of IQVIA worth $81,197,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Sowell Financial Services LLC acquired a new stake in shares of IQVIA in the first quarter valued at approximately $305,000. Mather Group LLC. boosted its position in IQVIA by 83.5% in the 1st quarter. Mather Group LLC. now owns 769 shares of the medical research company's stock valued at $136,000 after buying an additional 350 shares during the last quarter. Private Advisor Group LLC increased its stake in shares of IQVIA by 11.6% in the 1st quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company's stock valued at $958,000 after buying an additional 566 shares during the period. Park Avenue Securities LLC raised its position in shares of IQVIA by 40.4% during the first quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company's stock worth $956,000 after acquiring an additional 1,562 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in shares of IQVIA by 34.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company's stock valued at $2,338,000 after acquiring an additional 3,398 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Trading Up 0.6%

Shares of IQV stock traded up $1.06 on Wednesday, hitting $188.82. The stock had a trading volume of 1,014,432 shares, compared to its average volume of 1,950,944. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $252.88. The company has a fifty day moving average price of $174.96 and a two-hundred day moving average price of $167.97. The firm has a market cap of $32.10 billion, a P/E ratio of 27.33, a PEG ratio of 2.06 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The firm had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same period in the previous year, the company posted $2.64 earnings per share. The company's revenue for the quarter was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IQV has been the subject of several recent research reports. Robert W. Baird boosted their price objective on IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. Citigroup reiterated a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. Barclays increased their price objective on shares of IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a report on Wednesday, July 23rd. UBS Group upped their target price on shares of IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Finally, JPMorgan Chase & Co. reduced their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $228.62.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.